Earnings call: Tarsus reports strong Q1 with XDEMVY sales surge By Investing.com
Tarsus Pharmaceuticals, Inc. (TARS) has revealed robust financial results for the first quarter of 2024, with total revenues reaching $27.6 million, driven largely by the sales of its FDA-approved ...
32 minutes ago